Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Shweta Sharma, Shubham Srivastava, Apeksha Shrivastava, Ruchi Malik, Faisal Almalki, Khalid Saifullah, Mohammad Mumtaz Alam, Mohammad Shaqiquzzaman, Shakir Ali & Mymoona Akhter. (2020) Mining of potential dipeptidyl peptidase-IV inhibitors as anti-diabetic agents using integrated in silico approaches. Journal of Biomolecular Structure and Dynamics 38:18, pages 5349-5361.
Read now
Read now
Simona Cernea, Avivit Cahn & Itamar Raz. (2016) Saxagliptin for the treatment of diabetes - a focus on safety. Expert Opinion on Drug Safety 15:5, pages 697-707.
Read now
Read now
Rose Anderson, Jennifer Hayes & Jeffrey W. Stephens. (2016) Pharmacokinetic, pharmacodynamic and clinical evaluation of saxagliptin in type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 12:4, pages 467-473.
Read now
Read now
André J Scheen. (2015) Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opinion on Drug Safety 14:4, pages 505-524.
Read now
Read now
André J Scheen. (2015) A review of gliptins for 2014. Expert Opinion on Pharmacotherapy 16:1, pages 43-62.
Read now
Read now
André J Scheen. (2014) Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease. Expert Opinion on Drug Metabolism & Toxicology 10:6, pages 839-857.
Read now
Read now
Articles from other publishers (21)
Nourhan Samy Elmalahany, Muhammed Abdel‐Hamied Abdel‐Tawab, Hanan M. Elwy, Hussein M. Fahmy & Rasha M. El Nashar. (2023) Design and application of molecularly imprinted electrochemical sensor for the new generation antidiabetic drug saxagliptin. Electroanalysis 35:5.
Crossref
Crossref
Nicolas Bourdillon, Philippe J. Eugster, Céline Vocat, Toan Nguyen, Gregoire Wuerzner, Eric Grouzmann & Grégoire P. Millet. (2022) Saxagliptin: A potential doping agent? A randomized, double‐blinded, placebo‐controlled, and crossover pilot study in young active men. Physiological Reports 10:23.
Crossref
Crossref
Chen-Hung Lee, Shu-Chun Huang, Kuo-Chun Hung, Chia-Jung Cho & Shih-Jung Liu. (2022) Enhanced Diabetic Wound Healing Using Electrospun Biocompatible PLGA-Based Saxagliptin Fibrous Membranes. Nanomaterials 12:21, pages 3740.
Crossref
Crossref
Harshit Sajal, Shashank M. Patil, Ranjith Raj, Abdullah M. Shbeer, Mohammed Ageel & Ramith Ramu. (2022) Computer-Aided Screening of Phytoconstituents from Ocimum tenuiflorum against Diabetes Mellitus Targeting DPP4 Inhibition: A Combination of Molecular Docking, Molecular Dynamics, and Pharmacokinetics Approaches. Molecules 27:16, pages 5133.
Crossref
Crossref
Reema A. Khalaf, Dalal Masalha & Dima Sabbah. (2020) DPP-IV Inhibitory Phenanthridines: Ligand, Structure-Based Design and Synthesis. Current Computer-Aided Drug Design 16:3, pages 295-307.
Crossref
Crossref
Avinash MishraMegan CrossAndreas HofmannMark J. CosterAbdul KarimAbdul Sattar. (2019) Identification of a Novel Scaffold for Inhibition of Dipeptidyl Peptidase-4. Journal of Computational Biology 26:12, pages 1470-1486.
Crossref
Crossref
Athanasia Papazafiropoulou & Andreas Melidonis. (2019) Antidiabetic agents in patients with hepatic impairment. World Journal of Meta-Analysis 7:8, pages 380-388.
Crossref
Crossref
Nehad A. Abdallah & Heba F. Ibrahim. (2019) Electrochemical determination of Saxagliptin hydrochloride with MWCNTs/CuO/4′aminobenzo-18-crown-6-ether composite modified carbon paste electrode. Microchemical Journal 147, pages 487-496.
Crossref
Crossref
Joelle de Melo Turnes, Taysa Bervian Bassani, Leonardo C Souza & Maria A B F Vital. (2018) Ineffectiveness of saxagliptin as a neuroprotective drug in 6-OHDA-lesioned rats. Journal of Pharmacy and Pharmacology 70:8, pages 1059-1068.
Crossref
Crossref
Olivier Gaudin, Vannina Seta, Marina Alexandre, Gérôme Bohelay, Françoise Aucouturier, Sabine Mignot-Grootenboer, Saskia Ingen-Housz-Oro, Céline Bernardeschi, Pierre Schneider, Benoît Mellottee, Frédéric Caux & Catherine Prost-Squarcioni. (2018) Gliptin Accountability in Mucous Membrane Pemphigoid Induction in 24 Out of 313 Patients. Frontiers in Immunology 9.
Crossref
Crossref
L. Yu. Morgunov. (2017) DIABETES MELLITUS IN PATIENTS WITH LIVER CIRRHOSIS: NEW TREATMENT OPTIONS. Research'n Practical Medicine Journal 4:3, pages 75-85.
Crossref
Crossref
Shanshan Wu, Sanbao Chai, Jun Yang, Ting Cai, Yang Xu, Zhirong Yang, Yuan Zhang, Linong Ji, Feng Sun & Siyan Zhan. (2017) Gastrointestinal Adverse Events of Dipeptidyl Peptidase 4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-analysis. Clinical Therapeutics 39:9, pages 1780-1789.e33.
Crossref
Crossref
G. Penno, M. Garofolo & S. Del Prato. (2016) Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury. Nutrition, Metabolism and Cardiovascular Diseases 26:5, pages 361-373.
Crossref
Crossref
Jinguang Ruan. (2015) Serum Alanine Transaminase Total Bilirubin Concentrations Predict CYP3A Activity as Measured by Midazolam and 1’-Hydroxylation. Medical Science Monitor 21, pages 396-402.
Crossref
Crossref
André J. Scheen. (2014) Pharmacokinetics and Clinical Use of Incretin-Based Therapies in Patients with Chronic Kidney Disease and Type 2 Diabetes. Clinical Pharmacokinetics 54:1, pages 1-21.
Crossref
Crossref
Boaz Hirshberg, Artist Parker, Helen Edelberg, Mark Donovan & Nayyar Iqbal. (2014) Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus. Diabetes/Metabolism Research and Reviews 30:7, pages 556-569.
Crossref
Crossref
André J. Scheen. (2014) Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus. Clinical Pharmacokinetics 53:9, pages 773-785.
Crossref
Crossref
Omprakash Tanwar, Lalima Tanwar, Md. Shaquiquzzaman, Md. Mumtaz Alam & Mymoona Akhter. (2014) Structure based virtual screening of MDPI database: Discovery of structurally diverse and novel DPP-IV inhibitors. Bioorganic & Medicinal Chemistry Letters 24:15, pages 3447-3451.
Crossref
Crossref
Carlo B. Giorda, Elisa Nada & Barbara Tartaglino. (2014) Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature. Endocrine 46:3, pages 406-419.
Crossref
Crossref
María Laura Sbaraglini, María Silvina Molinuevo, Claudia Sedlinsky, León Schurman & Antonio Desmond McCarthy. (2014) Saxagliptin affects long-bone microarchitecture and decreases the osteogenic potential of bone marrow stromal cells. European Journal of Pharmacology 727, pages 8-14.
Crossref
Crossref
Joel M. Neutel, Cathy Zhao & Chetan S. Karyekar. (2013) Adding Saxagliptin to Metformin Extended Release (XR) or Uptitration of Metformin XR: Efficacy on Daily Glucose Measures. Diabetes Therapy 4:2, pages 269-283.
Crossref
Crossref